


CosMx Spatial Molecular Imager Spatial and Molecular Analysis of the Tumor Microenvironment



Spatial Context: Gene Expression plus Tissue Architecture

No two tumours are the same, and individual cells behave differently even within a single tumour. Spatial characterization of the tumour microenvironment, including immune infiltration, cell-cell interactions, and spatially defined cell states, can support identification of novel therapeutic targets and help define patient subgroups. While standard sequencing technologies pinpoint which genes are expressed - but not where and in which cells - cutting-edge technologies such as the CosMx Spatial Molecular Imager (SMI) add this valuable spatial context.

CosMx Spatial Molecular Imager Technology

CosMx SMI is an end-to-end solution for spatial analysis at subcellular resolution, within intact tissue. It enables highly multiplexed detection of over 18k different genes, and can also support multiomic gene and protein expression analysis. Interactive data analysis and visualization software support robust analysis.

Altogether, the CosMx SMI supports precise spatial localisation of transcripts and detailed mapping of cell states and tissue architecture. Drug developers can leverage it for discovery of new cell types in the tumor microenvironment (TME), immune cell identification and quantification, functional qualification, and exploration of spatial interactions.

Access Through a Demonstrator Project

We offer access to CosMx technology through our Therapeutic Vaccines Workstream.

Within Demonstrator Projects, and in collaboration with the Leiden University Medical Center-based lab of Professor Sjoerd van der Burg, you can:

- Profile gene and protein expression at single-cell and subcellular resolution in intact FFPE or fresh-frozen tumour tissue, healthy tissue, or organoids
- Analyze the full transcriptome with subcellular spatial information preserved, using patient-derived samples accessible through the Oncode Accelerator Organoids and Patient Cohorts Platforms
- Access support from expert users for experimental design and spatial data analysis

Get Started

Get started with your application today by contacting our Business Development team at: <https://www.oncodeaccelerator.nl/get-started>

Demonstrator Projects

Demonstrator Projects are collaborative, co-funded preclinical development projects that use our integrated infrastructure. We focus on four therapeutic modalities represented by our Workstreams:

- small molecules,
- biologics,
- cell & gene therapies, and
- therapeutic vaccines.

These preclinical drug development pipelines combine our state-of-the-art drug development pipelines with innovations from our Platforms:

- artificial intelligence (AI),
- organoid models and organ-on-a-chip technology, and
- well-defined data and materials from our patient cohorts.



**Oncode
Accelerator**

The Oncode Accelerator Project receives funding from the Dutch National Growth Fund (NGF). It is a collaboration between 6 coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht, and the Oncode Accelerator Foundation, who lead individual consortia within the Oncode Accelerator Project.